Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.
Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Castelnuovo B, et al. Among authors: bates m. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb;8(1):52-9. doi: 10.1177/1545109708328538. Epub 2008 Dec 17. J Int Assoc Physicians AIDS Care (Chic). 2009. PMID: 19095630 Clinical Trial.
Baseline HIV type 1 coreceptor tropism predicts disease progression.
Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, Coakley EP, Gomperts ED, Donfield SM; Hemophilia Growth and Development Study. Daar ES, et al. Among authors: bates m. Clin Infect Dis. 2007 Sep 1;45(5):643-9. doi: 10.1086/520650. Epub 2007 Jul 20. Clin Infect Dis. 2007. PMID: 17683002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. Shulman NS, et al. Among authors: bates m. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7. doi: 10.1097/00126334-200210010-00001. J Acquir Immune Defic Syndr. 2002. PMID: 12394789 Clinical Trial.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. Among authors: bates m. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Haubrich RH, et al. Among authors: bates m. HIV Clin Trials. 2007 Mar-Apr;8(2):63-7. doi: 10.1310/hct0802-63. HIV Clin Trials. 2007. PMID: 17507321 Clinical Trial.
1,374 results